Literature DB >> 2666452

Lack of interaction between sulindac or naproxen and propranolol in hypertensive patients.

A A Schuna1, B D Vejraska, J G Hiatt, M Kochar, R Day, T L Goodfriend.   

Abstract

Seventeen patients with hypertension and osteoarthritis participated in a single-blind crossover study comparing the effects of sulindac 200 mg twice daily, naproxen 500 mg twice daily, and placebo on blood pressure. All patients were treated for hypertension with propranolol monotherapy. Blood pressures were back-titrated to achieve a baseline diastolic blood pressure of 90 to 100 mm Hg while taking naproxen. There were no significant differences in mean sitting or standing blood pressures among the patients receiving naproxen, sulindac, or placebo treatments. There was no change in pulse, weight, or any of the laboratory measurements at the end of each treatment phase. These results suggest that neither sulindac nor naproxen interferes with propranolol therapy for uncomplicated hypertension.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2666452     DOI: 10.1002/j.1552-4604.1989.tb03375.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

Review 1.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of sulindac. A dynamic old drug.

Authors:  N M Davies; M S Watson
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

3.  Interaction of indomethacin and sulindac with labetalol.

Authors:  M A Abate; J L Neely; R D Layne; R D'Alessandri
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 4.  Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

Review 5.  Drug interactions in hypertensive patients. Pharmacokinetic, pharmacodynamic and genetic considerations.

Authors:  Y W Lam; A M Shepherd
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.